Dr. John Cush RheumNow
2 years 9 months ago
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD
Dr. John Cush RheumNow
2 years 9 months ago
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/IagcDC24rZ
Dr. John Cush RheumNow
2 years 9 months ago
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi
Dr. John Cush RheumNow
2 years 9 months ago
#RNL2023 - Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Uh2RFrfpc2
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.
When I was accepted into medical school, my Dad (a trauma surgeon) taught me that as a doctor I should not judge and do my best not to let my personal views interfere with how I manage and interact with my patients.
Dr. John Cush RheumNow
2 years 9 months ago
NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain &; odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/IcIQwP9z7C
Dr. John Cush RheumNow
2 years 9 months ago
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB
Dr. John Cush RheumNow
2 years 9 months ago
Study compared 491 SLE pts tested for ANCA Abs w/ 171 ANCA-associated vasculitis (AAV) pts. 46 SLE pts were ANCA+. ANCA-positive LN have worse baseline renal function and lower protein remission rates . https://t.co/fQCkBXJpO4
Dr. John Cush RheumNow
2 years 9 months ago
200 Biologic naive #RA pts in remission under csDMARD tapering and withdrawal while given either placebo or oral curcumin (1 g bid). Flare-free survival at 52 wks was similar between groups (60% vs 64%; p = 0.76). Time to flare was similar (219d vs 214d) https://t.co/m3j8HmjTT3 https://t.co/jDoAYN0eKQ
Dr. John Cush RheumNow
2 years 9 months ago
SGLT2 Inhibitors as Gout Treatment. Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said. https://t.co/zJVJuvCoIm https://t.co/kDLJynYczc
Dr. John Cush RheumNow
2 years 9 months ago
QD Clinic - Great Rheum Meetings
What makes for a great Rheumatology CME meeting?
https://t.co/tdb2crz8XP https://t.co/ZnMIhZpejO
Dr. John Cush RheumNow
2 years 9 months ago
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/szffvXtwaS
Dr. John Cush RheumNow
2 years 9 months ago
Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
https://t.co/WZcJugj3Bg https://t.co/HQ3Xg9h0md
